KACTUS is hosting a live webinar on September 21 featuring Anil Kumar PhD, Business Development Manager at KACTUS, to explore transmembrane protein display technologies.
Published
Signal category
Presence & Recognition
Quote
“Register now for our September 21 live webinar”
— KACTUS team
Company
KACTUS
Design and manufacturing recombinant proteins: antigens for antibody drug discovery, MHC complexes, and GMP enzymes.
- Industry
- Biotechnology Research
- Location
- Waltham, US
- Company size
- 38 employees
KACTUS is a biotechnology company serving global biopharma and diagnostics customers. We focus on commercial protein production for unmet needs in the drug development pipeline, including challenging recombinant proteins such as Claudin 18.2, MHC complexes, GPCR, CD20, and highly bioactive mRNA capping enzymes. Our goal is to deliver first-to-market innovative protein and antibody products. We also offer custom protein production including both research-grade and GMP-grade material. SAMS™ Technology Platform Our proprietary Structure Aided Design & Multiplex Screening (SAMS™) platform uses bioinformatics and 3D modeling to create vast search spaces for protein configurations. Expression conditions are optimized in vitro to identify settings that produce a natural protein configuration with bioactivity in multiple cell lines/settings. Quality KACTUS performs strict quality control testing on all our products including endotoxin levels. We also have facilities compatible with U.S. FDA cGMP guidelines to produce GMP-grade material. Our GMP-level partnerships are designed to provide you with routine bulk supply of material and supporting documentation to bring you from the R&D stage to commercial manufacturing and regulatory submission. In addition, our SAMS™ platform will assist in custom scientific optimization of your reagent.
Founded 2018